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1. Introduction 
1.1 Breast cancer and risk factors 
Breast cancer is the most common female cancer, the second most common cause of cancer 
death in women, and the main cause of death in women ages 40 to 59 (1). It has been 
reported that mortality rate from breast cancer has been significantly greater in women 
whose cancer was first diagnosed during pregnancy compared with those who had never 
been pregnant (2). Nowadays, many women all over the world faced the challenge of living 
with breast cancer. The lifetime probability of developing breast cancer is one in six overall 
(3). High prevalence of breast cancer and high mortality rate of women who stricken by, 
appoint it among the most challenging subjects in the area of experiments. The two major 
types of breast cancer risks are objective and subjective factors. Objective breast cancer risk 
is defined as an estimated chance for bearing breast cancer based on scientifically 
established risk factors for the disease and is predictive of resultant health outcomes. 
Subjective breast cancer risk is identified as an individual’s realization of her chance for 
getting breast cancer based on her own cognitive appraisal and is affected by depressive 
conditions. Objective BC risk had a limited but significant relationship with immune 
response and natural killer cell activity (NKCA), whereas Subjective risk was highly 
associated with psychological distress but was not associated with NKCA also the results 
are still controversial (4). 
Many factors including prenatal conditions, diet, physical activity, estrogen exposure, body 
mass index, depression and quality of life have been mentioned as breast cancer risk factors. 
A positive family history is the main risk factor. Diet with high amounts of alcohol, fat, 
caffeine and red meat is a positive risk factor for bearing breast cancer, whereas 
phytoestrogens and high amounts of calcium/vitamin D can be effective to reduce it (5,6).  
Hormonal conditions stand among the most important factors. Prolonged exposure to and 
higher concentrations of endogenous estrogen; which is controlled and modulated by 
menarche, pregnancy, and menopause; increase the risk of breast cancer. Testosterone level 
has also showed some parallelism with higher rate of breast cancer in some studies, 
although not in all of them. Younger age of menarche and older age of first full-term 
pregnancy are associated with a higher risk of breast cancer. The data about the effects of 
oral contraceptives on breast cancer risk are controversial. Some studies show an increased 
risk of breast cancer in oral contraceptive users, whereas in some other researches, no 
significant difference was seen. The two newer researches didn’t give any data which show 
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that oral contraceptives cause any increase in breast cancer risk. Long term use of post-
menopausal hormone therapy is associated with higher risk of breast cancer. In contrast, 
short-term HT appears not to increase the risk significantly, although it may make 
mammographic detection more difficult. Environmental toxic agents such 
as Organochlorines include polychlorinated biphenyls (PCB's), dioxins, and organochlorine 
pesticides such as DDT are weak estrogens with high lipophilic properties and as a result, 
can store in adipose tissues. Some studies suggest that exposure to these chemicals will 
increase the risk of bearing breast cancer, however the data are controversial and more 
researches should be done. 
Age and gender are among the strongest risk factors for breast cancer. Breast cancer occurs 
100 times more frequently in women than in men. Incidence rates increase with age until 
about the age of 45 to 50. 
Ethnic difference is another factor affecting breast cancer prevalence. For example, in United 
States, breast cancer is more common among whites. Much of these differences arise from 
lifestyle factors and social conditions. Furthermore, there are marked variations in breast 
cancer incidence and mortality among countries Women with higher educational, 
occupational and economic level are at greater risk because of their reproductive pattern 
including age of parity and age of first birth. Ethnic differences in estrogen and 
progesterone receptor subtypes have been also determined as important factors that affect 
the probability of breast cancer (7). In a Multiethnic Cohort Study, various status of estrogen 
receptor (ER)/progesterone receptor (PR) including ER-/PR-, ER+/PR+, ER-/PR+ and 
ER+/PR- have been reported and ER/PR status varied significantly across racial/ethnic 
groups even within the same tumor stage. Compared to whites, the high prevalence of 
hormone receptor-negative tumors in African-American women may contribute to their 
high breast cancer mortality (8).  
2. Breast cancer classification 
Nowadays, beside conventional use of grade, histology, and immunohistochemical analysis, 
changes in gene expression during bearing tumors are used as an instrument to classify 
breast cancer. Molecular profiling make us capable for better understanding of breast 
cancer, more precision in determining subtypes and better prediction of clinical outcome 
and response to therapy. New instruments like microarray kits provide the possibility for 
simultaneous studying of the expression of thousands of genes in a breast cancer cells and 
finding out the Gene expression profile. Future applications will take the same approach to 
proteins (proteomics), genome-wide germline variability (single nucleotide 
polymorphisms), or cellular metabolism (metabolomics). Based on these methods, several 
distinct breast cancer subtypes have been identified including two main subtypes of 
estrogen receptor (ER)-negative tumors and basal-like and human epidermal growth factor 
receptor-2 (HER2)-enriched, and two subtypes of ER-positive tumors including luminal A 
and luminal B. These subtypes differ markedly in prognosis and in the therapeutic targets 
they express. 
The luminal cancers, luminal A and luminal B, so called because they are characterized by 
expression of genes also expressed by normal breast luminal epithelial cells, have overlap 
with ER-positive breast cancers. There are also several subtypes characterized by low 
expression of hormone receptor-related genes (ER-negative), one of which is called the 
"HER2-enriched" subtype (previously called HER2+/ER-) and another called the "basal-like" 
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subtype. The basal-like subtype is named because it expresses many genes characteristic of 
normal breast basal epithelial cells. 
3. Luminal subtypes 
The name "luminal" derives from similarity in expression between these tumors and the 
luminal epithelium of the breast; they typically express luminal cytokeratins 8 and 18. These 
are the most common subtypes, make up the majority of ER-positive breast cancer, and are 
characterized by expression of ER, PR, and other genes associated with ER activation. 
3.1 Luminal A and luminal B traits 
High expression of ER-related genes, low expression of the HER2 cluster of genes, and low 
expression of proliferation-related genes are the two main characters of Luminal A tumors. 
This kind has the best prognosis of all breast cancer subtypes. Whereas luminal B tumors 
have relatively lower (although still present) expression of ER-related genes, variable 
expression of the HER2 cluster, and higher expression of the proliferation cluster. 
Luminal B tumors carry a worse prognosis than luminal A tumors. Unfortunately, this 
subtype has high probability of recurrence. 
3.2 HER2-enriched subtype 
The HER2-enriched subtype (previously the HER2+/ER- subtype) is characterized by high 
expression of the HER2 and proliferation gene clusters, and low expression of the luminal 
cluster. For this reason, these tumors are typically negative for ER and PR, and positive for 
HER2. It is important to note that this subtype comprises only about half of clinically HER2-
positive breast cancer. The rest have high expression of both the HER2 and luminal gene 
clusters and fall in a luminal subtype. Promotion in HER2-directed therapy has improved 
the poor prognosis of this subtype. 
3.3 Basal-like subtype 
The name of “basal-like” subtype comes from the similarity in gene expression to that of the 
basal epithelial cells. This subtype shows lower expression of the luminal and HER2 gene 
clusters. Therefore, these tumors are typically ER-, PR-, and HER2-negative on clinical 
assays. Because of this reason, the name "triple negative" is also used to describe them. 
However, while most triple negative tumors are basal-like, and most basal-like tumors are 
triple negative, there is significant inconsistency (up to 30 percent) between these two 
classifications. Although any subtype can be triple negative on clinical assays, an interesting 
subtype found in non-basal triple negative breast cancers is the more newly described 
claudin-low subtype, which is uncommon but interesting because of its expression of 
epithelial-mesenchymal transition genes and characteristics reminiscent of stem cells (9). 
Recently, many studies have focused on finding molecular pathways that play some roles in 
breast cancer pathogenesis. Mutation in oncogenes, pro-oncogenes and tumor suppressor 
genes has been remarked as potential elements in breast cancer. DNA amplification (mostly 
in proto -oncogenes, growth factors and their receptors) and DNA deletion (in tumor-
suppressor genes) are repeatedly observed in breast tumors. Berouk him et al. found 76 
amplifications and 82 deletions in 243 breast tumors, in regions containing new possible 
sensitive genes, such as MCL1 and BCL2L1 (apoptosis), Interleukin-1 receptor-associated 
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kinase1 (IRAK1), TNF receptor associated factor (TRAF) 6, IKBKG which codes NF-kappa-B 
essential modulator (NEMO) protein and IKBKB which codes inhibitor of nuclear factor 
kappa-B kinase subunit beta (IKK-ǃ) protein in NK- kB signaling pathway. PIK 3CA, the 
gene encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is mutated in 
about 20 – 30% of breast tumors. TP53 mutations are found in about 30 – 35% of cases (10). 
Two newly identified genes, BRCA1 (Breast Cancer gene A1) and BRCA 2 (Breast Cancer 
gene A2), have been identified and categorized as human tumor suppressor genes. 
Mutations in these two genes have been found in the majority of hereditary breast cancer 
cases. Until the age of 70 women with mutated BRCA1 or BRCA2 genes faces to 45-85% 
increase in the risk of developing breast cancer. Several studies have demonstrated that 
patients with mutation in BRCA1 usually bear triple-negative kind breast tumors. In 
contrast, pathologic characteristics of BRCA2-mutant cases did not seem to be very different 
with non-carriers. Both these two genes play important roles in DNA repair in a common 
pathway. BRCA 1 is necessary for mammary stem cell differentiation, a function that could 
explain its tissue-specificity.  
Mutations usually result in dysregulation of signal transduction pathways. Increased 
expression of specific receptor tyrosine kinases (RTKs) has been implicated in the genesis of 
a significant proportion of sporadic human breast cancers. Increased activity of some of 
tyrosine kinases can result in aberrant cell proliferation. This phenomenon may result in cell 
transformation. For example, amplification and overexpression of neu/erbB2 proto-
oncogene is observed in 20–30% human breast cancer, and is inversely correlated with the 
survival of the patient. 
The epidermal growth factor receptor (EGFR) family is a member of growth factor receptors 
which consists of four members: EGFR, ErbB2/Neu, ErbB 3, and ErbB 4. Increase ErbB2 
expression, has been further associated with poor clinical outcome, is observed in 20 – 30% 
of sporadic breast tumors. The main reason is ErbB2 gene amplification (11). Increased level 
of tyrosine phosphorylated ErbB3 has been also reported. The important point is that ErbB3 
is a bridge which links the phosphatidyl inositol-3 kinase (PI-3K) signaling molecule to Neu 
which has attracted much attention because of its potent transforming properties. This 
oncogene activates a number of common signaling pathways by providing specific binding 
sites for a variety of signaling molecules that include either Src Homology 2 (SH2) or 
phosphotyrosine binding/interacting domains. Co-expression of ErbB2 and ErbB3 RTKs is 
usually observed in common tumor progression (11,12). 
 Mammary epithelial expression of Polyoma virus middle T (PyV mT) antigen, another 
tyrosine kinase involved in murine mammary tumorigenesis and metastasis, results in the 
rapid induction of multifocal metastatic mammary tumors. Since these tumors occur during 
early steps of mammary gland development and involve whole of the gland, expression of 
PyV mT will result in transformation of the primary mammary epithelium. This molecule is 
also associated with many signaling pathways via Src Homology 2 (SH2) or 
phosphotyrosine binding/interacting domains (13). 
It has been shown that Activated growth factor receptors can interact with integrin receptors 
and control their biological function in cancerous cells. An example is the stimulation of 
a6ß1 integrin through association with activated members of the EGFR family which 
conversely results in activation of EGFR family phosphorylation. Induction of tumor by the 
PyV M T oncogene is also dependent on the presence of functional ß1-integrin. Lack of 
functional ß1-integrin makes tumor cells unable to enter the cell cycle. Although, these 
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tumor cells are unable to proliferate, There are still viable and bears pathological tumor 
dormancy. Interesting point is that inhibition of integrin-mediated FAK signaling will also 
shows the similar pathological features. ß4integrin, other member of integrin family, has 
shown a clear role cell proliferation and invasion through association with Erb B2. Not all 
integrins, however, have a role in bearing cancer. Deficiency in ß3 or/an d ß 5 integrins did 
not produce much difference in tumor growth, tumor numbers or lung metastasis in the 
PyV MT mouse model , only a little increase in tumor onset was observed. Taken together, 
these observations give promising data for targeting integrin receptors and their associated 
signaling pathways as a new treatment of breast cancer (11).  
Activation of the phosphatidyl inositol-3 kinase is also important in mammary tumor 
progression. Association of PI-3K links to PyV mT through its binding to phosphotyrosine 
residues (Tyr 315/322) within the PyV mT coding sequences. Association with Neu happens 
through recruitment to ErbB3 (ErbB, is derived from the name of a viral oncogene to which 
these receptors are homologous: Erythroblastic Leukemia Viral Oncogene). Activation of PI-
3K and resultant production of phosphoinotide-3 lipids stimulates several members of 
serine kinase family. The final of these cascades will be the stimulation a number of 
antiapoptotic signaling molecules such as nuclear factor-kB (NF- κB) (14,15) 
4. Role of NF- κB 
Because of the wide range of activities of transcription factor NF- κB in apoptosis and cell 
survival and cell proliferation pathways as well as cell adhesion and angiogenesis it plays a 
remarkable role in tumorigeneses.  
Regulatory influence of NF- κ B on the expression of various tumor-promoting molecules 
such as MMP, cycloxygenase 2, inducible nitric oxide synthase, chemokines, and 
inflammatory cytokines explain its significant effect on bearing cancer. NF- κB increased the 
expression of these molecules, all of which enhance tumoral cell invasion and angiogenesis. 
Other aspect of the role of NF- κB in tumorigeneses includes increasing expression of proto-
oncogenes such as c- myc and cyclin D1 which directly stimulate proliferation. (14)  
4.1 Adapter proteins 
Adapter proteins do not exert any kinase activity, but they regulate protein – protein 
interaction and help the formation of protein complex which participate in signal 
transduction pathways. GRB2-associated-binding protein 2 (Gab2) is one of the adapter 
proteins which is overexpressed in breast cancer. It promotes signaling pathways by 
recruiting SH2 containing proteins such as PI3K, Shc, and Shp2 downstream of tyrosine 
kinase receptors. Although elevated expression of Gab2 in the mammary epithelium is 
unable to induce tumor development, it has been shown that tumor onset time will decrease 
in presence of Gab2 (16,17)  
4.2 Activation of the Ras signaling pathway 
Activation of the Ras signaling pathway is commonly observed in mammary tumor 
progression. Adapter proteins such as Shc and Grb2 create some specific complexes with 
activated forms of Neu and PyV mT. The co-operation of Grb2 and Shc with these activated 
oncoproteins will result in stimulation of Ras signaling. In contrast to PyV mT, which 
signals to Ras only through its association with Shc, Neu can activate Ras through Grb2, Shc 
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and several other unidentified adapter proteins. Resultant phenomenon of  Ras activation 
will be the recruiting of a number of downstream effector molecules including PI-3K, Raf 
serine kinase, GRB associated-binding protein  (GAP) and Ras-related protein (Ral) (16). 
Figure 1 presents an overview of Ras/MAPKs signaling pathway. 
 
 
Fig. 1. MAPKs cascades Mitogen-activated protein kinases (MAPK) are a family of 
Ser/Thr protein kinases widely conserved among eukaryotes and are involved in many 
cellular programs such as cell proliferation, cell differentiation, cell movement, and cell 
death. MAPK signaling cascades are organized hierarchically into three-tiered modules. 
MAPKs are phosphorylated and activated by MAPK-kinases (MAPKKs), which in turn 
are phosphorylated and activated by MAPKK-kinases (MAPKKKs). The MAPKKKs are in 
turn activated by interaction with the family of small GTPases and/or other protein 
kinases, connecting the MAPK module to cell surface receptors or external stimuli. 
[Source: Pathway diagram reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com).] 
5. Dysregulation of cell cycle 
Dysregulation of cell cycle can also results in malignant cell proliferation and 
Tumorigenesis. Cyclin D1, for example, has been reported to be overexpressed in human 
breast cancer (18). Observation has been confirmed in MMTV-Ras and MMTV-Neu mice 
deficit in Cyclin D1. Tumor development completely stops in these animals which show the 
critical role of Cyclin D1 in Ras-Neu transformation pathway..Although overexpression of 
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Cdc25b make mammary glands hyperplasic and more sensitive to carcinogenic chemicals, it 
does not directly induce tumorigeneses. Recently, inhibitor of nuclear factor kappa-B kinase 
(IKK a, a responsible kinase for activation of NF-k B, was identified as a necessary factor for 
Cyclin D1-associated epithelial proliferation in MMTV-Neu (but not in MMTV- Ra s) mice 
(11).  
5.1 The role of extracellular matrix (ECM) enzymes 
In addition to integrin family, which has discussed above, the role of other extracellular 
matrix (ECM) enzymes such as cathepsins and plasmin in tumorigensis and metastasis has 
attracted much attention (19,20) 
Matrix metalloproteinases (MMP) are a family of matrix degrading enzymes associated with 
tumor progression, metastasis, and poor prognosis. A tumor cell must degrade the 
surrounding stroma to reach blood vessels. That’s why it is thought that these degrading 
enzymes control the primary step in invasion and metastasis. The roles ofMMP2, 
MMP3,MMP7 and MMP9 have been established (21,22). 
urokinase-type plasminogen activator (uPa ) is another extracellular degrading enzyme 
which cleaves plasminogen into plasmin. The latter can degrade ECM directly or indirectly 
via activating MMPs. PyV MT -associated lung metastasis shows remarkable decrease was 
in plasminogen-deficient mice as well as in uPa-deficient mice (11,23).  
5.2 Mutations in tumor suppressor genes 
Transforming growth factor-ß (TGF- ß) is a secreted cytokine which induces s growth arrest 
in normal epithelium. It interacts with the TGF- ß type II receptor (T ß RII) which followed 
by recruitment and phosphorylation of TGF- ß type I receptor (Tß RI) and activation of 
downstream signaling cascade. The cytostatic effect of TGF- ß is also seen on early tumor 
progression and is mediated through the regulation of both apoptosis and cell proliferation. 
However, TGF-ß signaling increases lung metastasis in some transgenic mouse models. 
Breast carcinomas are well known for overexpressed TG F- ß. Induct ion of TGF- ß 1 after 
tumor initiation do not exert much effect on proliferation of tumor, but remarkably increase 
the lung metastasis. These data support the hypothesis that that TGF -ß 1 may no longer 
perform an inhibitory role in established tumors (24). 
Another important tumor suppressor associated with mammary tumor development is p53. 
p53 is well-known for its involvement in a variety of cancer types. P53 gene is one of the 
most altered tumor suppressor genes in human breast cancer, such that around 50% of all 
breast cancers include mutated form of p53 gene (25).  
It has been reported that Insulin-like Growth Factor (IGF) may have effect in breast cancer 
progression. It has been showed that Retinoic Acid (RA) mediate their inhibitory effects on 
cell growth of cancerous human breast cancer cells “MCF7” via selective reduction of 
Insulin Receptor Subtype-1 (IRS-1) and its activity which results in the selective down-
regulation of IP3-kinase/AKT. High levels of Irs-1 in human breast tumors correlate with 
elevated incidence of disease recurrence. Although the insulin receptor substrates (IRS) were 
primarily identified, as the name implied, as a substrate for the insulin receptor (IR), 
Nowadays it has been known that these adapter proteins, are involved in activation of 
downstream pathways of several growth factor receptors such as insulin-like growth factor-
1 receptor (IGF-1R), vascular endothelial growth factor receptor (VEGF-R), cytokine  
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Fig. 2. PI3K / Akt Signaling.The Akt cascade is activated by receptor tyrosine kinases, 
integrins, B and T cell receptors, cytokine receptors, G protein coupled receptors and other 
stimuli that induce the production of phosphatidylinositol 3,4,5 triphosphates (PtdIns(3,4,5)P3) 
by phosphoinositide 3-kinase (PI3K). These lipids serve as plasma membrane docking sites for 
proteins that harbor pleckstrin-homology (PH) domains, including Akt and its upstream 
activator PDK1. There are three highly related isoforms of Akt (Akt1, Akt2, and Akt3) and 
these represent the major signaling arm of PI3K. For example, Akt is important for insulin 
signaling and glucose metabolism, with genetic studies in mice revealing a central role for 
Akt2 in these processes. Akt regulates cell growth through its effects on the mTOR and p70 S6 
kinase pathways, as well as cell cycle and cell proliferation through its direct action on the 
CDK inhibitors p21 and p27, and its indirect effect on the levels of cyclin D1 and p53. Akt is a 
major mediator of cell survival through direct inhibition of pro-apoptotic signals such as Bad 
and the Forkhead family of transcription factors. T lymphocyte trafficking to lymphoid tissues 
is controlled by the expression of adhesion factors downstream of Akt. Figure 2 presents a 
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general map from the role of AKT and the signaling crosstalk which discussed above. In 
addition, Akt has been shown to regulate proteins involved in neuronal function including 
GABA receptor, ataxin-1, and huntingtin proteins. Akt has been demonstrated to interact with 
Smad molecules to regulate TGFǃ signaling. Finally, lamin A phosphorylation by Akt could 
play a role in the structural organization of nuclear proteins. These findings make Akt/PKB an 
important therapeutic target for the treatment of cancer, diabetes, laminopathies, stroke and 
neurodegenerative disease. [Source: Pathway diagram reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com).] 
receptors, and some members of the integrin family. Interestingly, loss of either IRS -1 or IRS 
-2 did not show similar consequence on developing lung metastasis. Metastasis will increase 
in IRS -1-deficient tumors, IRS-2-deficient tumors shows decreased lung metastasis. It is 
thought that a compensatory mechanism which upregulate IRS-2 expression is involved in 
the increased metastasis seen in IRS-1-deficient tumors. These results are very similar to the 
ones seen with Akt1 and Akt2, where Akt1 was shown to inhibit invasion and metastasis 
while Akt2 perform in an opposite way. RA influence occurs at post-translational level by 
increase in ubiquitination and serine phosphorylation of IRS-1. The latter is protein-kinase C 
(PKC)-dependent, since PKC inhibitors block the process. Activation of PKC-ǅ by RA has 
also been reported. Activation of PI3K/PDK/Akt cascade also decreases sensitivity of MCF7 
cells to anticancer drugs. Induction of Bcl-2 may contribute to this resistance (26,27). Figure 2 
offers a comprehensive diagram which shows the role of PI3/Akt cascade in cellular 
functions. As it is seen, this pathway plays a vital role in cell proliferation and cell survival. 
Therefore, logically it is predictable that any signal disregulation in this cascade will be a 
risk factor for uncontrolled cell proliferation and malignancy. 
In one of the recently-performed experiments, the increasing influence of estradiol (E2) on 
expression level of iNOS in breast cancer cell line T47D were identified as a result for 
resistance to tamoxifen. In these cells, administration of oligomycin-2 deoxy glucose (2DG) 
enhanced tamoxifen antiproliferative effects, which may be due to exacerbated ATP depletion 
following tamoxifen and oligomycin-2DG co-administration. Oligomycin-2DG neither 
changed iNOS expression nor affected its attenuated expression due to tamoxifen exposure, 
suggesting that ATP depletion-mediated sensitivity to tamoxifen is apart from iNOS (28).  
6. Breast cancer stem cells  
Recently, cancer stem cells (CSCs) have attracted a lot of attentions and some roles have 
been determined for estrogen and progesterone by affecting these cells. It has become 
clear that the normal and malignant breast contains stem cells (SCs) that play an essential 
role in the normal development o f the breast and are likely to play a significant role in the 
genesis and growth of human breast cancer. The CSC hypothesis introduced tissue-
specific Stem Cells (SCs) and/or their early progenitors as the main causes of the 
malignant behavior of cancer. These cells are undifferentiated and, as a result, have the 
ability to divide into two daughter cells. But, division is asymmetrical and will cause an 
identical clone of the mother cell and another cell which can divide and fully differentiate 
into new cell line. This latter daughter cell is named a Progenitor. Physiological functions 
of breast SCs include producing the early milk ducts and the surrounding stroma at 
puberty and repair of damaged tissue and renovation the lost ductal and stromal cells 
during adult life. 
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In contrast to their progenitor and differentiated offspring, breast SCs are very long life and 
thus influences of the effect of chemicals and radiation. Since breast CSCs escape from the 
control of surrounding microenvironment, they are able to bear malignant progenitor 
offspring. The result will be the production of malignant daughter cells that create the bulk 
of the tumor.  
As a rare phenomenon, some of breast CSCs are quiescent and, as it is expected, will be 
spared by current cancer therapies whose targets are rapidly divided cells (29-32) 
6.1 Role of estrogens and progestins  
It has been suggested that hormone therapy or oral contraception may increase the risk of 
breast tumor development because of proliferation of existing quiescent tumor cells. The 
estrogen receptor-alpha (ERa) has an important role in normal breast cell development. 
Genetic alterations in the ER a gene locus might therefore have important effects in breast 
carcinogenesis. Polymorphisms can also cause even more increase in estrogen-associated 
breast cancer risk. At least three polymorphisms, i.e. the G478T, A908G, and C975C have 
been put in this category (33). 
 
 
 
Fig. 3. Effect of Estrogens and progestines on breast CSCs. CSCs divide into abnormal off-
spring which can differentiate to all types of breast tumoral cells 
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Progestins, on the other way, are able to upregulate growth factor and cytokine receptors at 
the cell surface. They are also involved in regulation of several intracellular effectors 
including Stat 5, and by potentiating mitogen-activated protein kinase (MAPK) and Janus 
kinase activities by increasing the levels and altering the subcellular compartmentalization 
of them at cytoplasmic level. Furthermore, growth factor-regulated nuclear transcription 
factors may have synergistic effect with PRs' agonists to regulate the function of key genes 
which are involved in breast cancer. (34) 
Recently, the influence of estrogen, progesterone, and progestins on breast CSCs and their 
progeny has been found out. As it has been demonstrated in figure 3, although most of 
breast CSCs are estrogen receptor negative and progesterone receptor negative, some 
intermediate progenitor forms own hormone receptors, especially progesterone receptor. 
Progesterone and progestin specially work on these breast cancer stem intermediate forms, 
inducing them to return back to a more primitive breast CSC forms, thus increasing the pool 
of malignant SCs (29). These cells escape the microenvironment control. Estrogens, on the 
other hand, induce the proliferation of these abnormal progenitors, resulting in breast 
tumor. Figure 3 summarize this hypothesis. 
7. P-glycoproteins and breast cancer resistance protein (Bcrp) 
P-glycoproteins and breast cancer resistance protein (Bcrp) also play important roles in resistance 
and therapeutic outcome of breast cancer therapy and mutations in MDR genes (which codes p-
glycoproteines) and influence the risk and resistance to treatment. Many drugs are substrates for 
this transporters and the reduction in their access to tissues can result in increase in metastasis 
and drug resistance. From glycoprotein family, glycoprotein non-metastatic B (GPNMB, also 
named as Osteoactivin) enhances breast cancer metastasis in an in vivo mouse model. It also has 
been studied as a prognostic indicator of recurrence. The data suggested this glycoprotein as a 
novel therapeutic target in breast cancer. GPNMB usually express in basal/triple-negative 
subtype of breast cancer and is associated with poor outcome (35).  
Fetuin-A is another glycoprotein which its role in mammary tumorigenesis has been studied.  
It is a serum component protein which forms approximately 45% of non-collagenous 
glycoproteins which is synthesized by the liver and excreted into plasma. It is a conserved 
member of the cysteine protease inhibitors which contains the TGF-ǃ receptor II homology 1 
domain (TRH1). As a result, it is able to compete with epithelial cells for TGF- ǃ. The 
possible sequestration of TGF ǃ by fetuin-A could affect TGF ǃ signaling in breast epithelial 
cells as previously reported for intestinal epithelial cells. Fetuin-A shows reduced incidence 
of mammary tumors for breast cancer by more than 60% and increases tumor onset. 
Another tumor-enhancer property of fetuin-A is its stabilizer effect matrix 
metalloproteinases in the extracellular matrix. 
Consequently, they can drive the “tumor islands” to invade the stroma metastasize to other 
organs. Stronger TGF-ß signaling in the absence of fetuin-A exert suppressor effect on cell 
proliferation through increase in is ARF-p53 expression, whereas the sequestration of TGF-ß 
by fetuin-A, results in reduction of its signaling in epithelial cells and inactivation of ARF-
p53 which is parallel with shortening the latency of mammary tumorigenesis and 
implications of breast cancer development (36). 
7.1 Astrocyte Elevated Gene-1 
Some newly reported show that elevation in expression level of astrocyte elevated gene-
1(AEG-1, also known as Metadherin and lyric) in human breast cancer dramatically 
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enhanced cell proliferation and their ability of anchorage-independent growth of breast 
cancer cells. These proliferative effects were significantly related to attenuation of two key 
cell-cycle inhibitors, p27Kip1 and p21Cip1, via Akt/ FOXO1 signaling pathway. FOXO1 is a 
transcription factor belonging to the Forkhead box-containing class O (FOXO) subfamily. 
Many biological functions have been shown to be related with FOXO1 including cell-cycle 
control, differentiation, stress response and apoptosis (37). FOXO proteins could act as 
tumor suppressors through induction of CDK inhibitors, including p21 Cip1, p27Kip1and 
p57 (38). Overexpression of AEG-1 increases migration and invasion of human glioma cells 
because of the presence of a lung-homing domain which facilitates breast tumor metastasis 
to lungs. Recent observations indicate that AEG-1 play this role by activating NF-κB 
pathway. Our recent observations indicate that, AEG-1 facilitates IκBa degradation, 
resulting in an increase in NF- κB DNA binding activity and NF- κB promoter activity in 
reporter assays These valuable findings are strengthen the idea which recommend AEG-1 as 
a crucial regulator of tumor progression and metastasis (39).  
Another considerable role attributed to AEG-1 is mediating a broad-spectrum 
chemoresistance. In vitro and in vivo studies showed that knocking down AEG-1 makes 
several different breast cancer cell lines more sensetive to paclitaxel, doxorubicin, cisplatin, 
4-hydroxy cylco phosphamide, hydrogen peroxide, and UV radiation mediated by the pro-
survival pathways such as PI3K and NFκ B, or through other downstream genes of 
MTDH/AEG-1 that directly regulate chemoresistance. AEG-1 has also resulted in 
chemoresistance neuroblastoma and prostate cancer. In fact, MTDH/AEG-1does not affect 
the uptake or retention of chemotherapy a. Instead,  
it enhances chemoresistance by increasing cell survival after chemotherapy. Data gathered 
from Microarray analysis of breast cancer cells showed reduction of expression of 
chemoresistance genes ALDH3A1, MET, HSP90, and HMOX1, and increased expression of 
pro-apoptotic genes BNIP3 and TRAIL after MTDH/AEG-1knocking down. Among these 
genes, ALDH3A1 and MET were established to partially be associated with the 
chemoresistance role of MTDH/AEG-1 in MDA-MB-231 breast cancer cells. Some other 
genes also contribute to chemoresistance including drug-metabolizing enzymes for different 
chemotherapeutic agents, such as dihydropyrimidine dehydrogenase (DPYD), cytochrome 
P4502B6 (CYP2B6), dihydrodiol dehydrogenase (AKR1C2), and the ATP-binding cassette 
transporter ABCC11 for drug efflux (40). Roles of MTDH/AEG-1 have been simplified in 
figure 4. 
There are some studies which suggest that Activated protein C (APC), an anticoagulant 
serine protease, is related to cell survival, cell migration, angiogenesis and breast cancer 
invasion. APC recruits EPCR, PAR-1, and EGFR in extracellular matrix in order to increase 
the invasive properties of MDA-MB-231 cells. Other mechanisms include activation of 
matrix metalloprotease (MMP) -2 and/or -9 and activation of ERK, Akt, and NF-κB (but not 
the JNK) pathways. APC does not employ the endogenous plasminogen activation system 
to increase invasion (41). 
7.2 Role of STAT family 
The Stat (Stands for signal transducer and activator of transcription) family of proteins are 
latent cytoplasmic transcription factors which are involved in cytokines signaling pathways. 
They are necessary for normal cell growth, survival, differentiation, and motility. STAT 
proteins need activation through tyrosine phosphorylation, which leads to dimerization via 
conserved structural features phosphotyrosine-SH2 (Src homology domain 2) of two Stat 
molecules. Fallowing activatin, Stats transport to the nucleus, where they bind to the 
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Fig. 4. MTDH/AEG-1 promotes tumor progression through the integration of multiple 
signaling pathways. Oncogenic Ha-Ras increases MTDH/AEG-1 expression through the 
activation of the PI3K/Akt pathway, which phosphorylates and inactivates GSK3ǃ, and 
subsequently enhances the stabilization and binding of c-Myc to the MTDH/AEG-1 
promoter. MTDH/AEG-1 can activate AKT, NFκB, and Wnt/ǃ-catenin pathways to 
promote proliferation, survival, and invasion. Activation of NFκB signaling is in part 
mediated by the direct interaction of MTDH/AEG-1 with p65 and CBP, a general 
transcriptional co-activator. MTDH/AEG-1 activates the Wnt/ǃ-catenin pathway through 
increasing the activity of MAPK kinases ERK and p38, which phosphorylates GSK3ǃ and 
stabilized ǃ-catenin. Furthermore, MTDH/AEG-1 increases the expression of LEF-1, a 
transcriptional cofactor for ǃ-catenin. The prometastasis function of MTDH/AEG-1 is 
mediated by the interaction of the LHD of MTDH/AEG-1 with an unknown receptor in 
endothelial cells. The broad spectrum chemoresistance function of MTDH/AEG-1 is 
mediated by a number of downstream genes that promote the resistance to multiple 
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chemotherapeutic agents. Proteins with direct interactions with MTDH/AEG1 are shown in 
green. Dotted line indicates pathways yet to be fully validated or characterized. [Source: 
Figure 1 from Ref. 40] With permission 
 
 
Fig. 5. Role of Stat3 signaling pathway to cancer metastasis. Activatin of STAT3 happens by 
recruitment to phosphotyrosine motifs within complexes of growth factor receptors (e.g., 
epidermal growth factor receptor), cytokine receptors (e.g., IL-6 receptor), or non-receptor 
tyrosine kinases (e.g., Src and BCR-ABL) through their SH2 domain. Stat3 is then 
phosphorylated on a tyrosine residue by activated tyrosine kinases in receptor complexes. 
Phosphorylated Stat3 forms homodimers and heterodimers and translocates to the nucleus. 
In the nucleus, Stat3 dimers bind to specific promoter elements of target genes and regulate 
gene expression. The Stat3 signaling pathway regulates cancer metastasis by regulating the 
expression of genes that are critical to cell survival, cell proliferation, invasion, angiogenesis, 
and tumor immune evasion. 
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promoter of target genes and activate their transcription. Dimerized status of STATs is 
transient in normal non-transformed cells. But in transformed cancerous cells, Stat proteins 
in particular, Stat3 are found in a permanent active dimerized manner. Activated form of 
STAT3 has been found in more than 50% of primary breast tumors and tumor-derived cell 
lines. It has been reported that expression of a constitutively active form of Stat3 (Stat3C) is 
sufficient for promoting cellular transformation and bearing an immortalized breast cell 
line. Since the IL-6/gp130/Jak signaling pathway has a crucial role in Stat3 activation in 
human breast cancer, blockade of this pathway may be an important therapeutic plan in 
breast cancer therapy (42). Role of STAT3 has been shown in figure 5 
As it is mentioned above, dysregulation protein expression can result in increased metastatic 
properties of breast cancer. As a fact, reduction in cell adhesion and increased cell motility is 
necessary for tumor metastasis. Therefore, cell adhesion molecules have roles in promoting 
and inhibiting metastasis. Specific families of adhesion molecules including selectins, 
integrins, lectins, and cadherins have been established to be associated with metastasis (43-
47). The cells have to pass the basement membrane to reach the surrounding vessels and 
spread to other sites. This process involves proteolysis and motility and need proteolytic 
enzymes to work. Three major categories of proteolytic enzymes including the matrix 
metalloproteinases (48), serine proteinases, and cathepsins (discussed above) are implicated 
in metastasis. Cell motility is another factor which cells need to be able to metastasize to 
other tissues. Several factors are necessary for cellular motility, including the autocrine 
motility factor, autotaxin, and hepatocyte growth factor (HGF). HGF will result in 
developing more as well as larger axillary lymph node metastases (24). 
Chemoattractants and their corresponding receptors are the other factors affecting 
metastasis rocess. Osteonectin (a glycoprotein secreted by osteoblasts in bone, initiating 
mineralization and promoting mineral crystal formation) engages breast and prostate cancer 
cells to bone. Recently presented data indicate that chemokine receptors CXCR4 and CCR7 
express in breast carcinoma cells predisposed for metastasis to lymph nodes and bone (24). 
Metastasis-associated protein 1 (MTA1) mRNA expression is parallel to metastatic potential. 
Function of the MTA1 gene product in tumor progression and metastasis is still unknown, 
although it is thought that MTA1 is found in the chromatin remodeling histone deacetylase 
complex (24). 
Osteopontin was identified as a metastasis associated gene. Osteopontin appears to be 
useful for prognosis in that elevated plasma levels and immunohistochemical staining of 
tumor cells are found in metastatic breast cancer patients. It is important, however, to note 
that not all studies show correlations. For example, immunohistochemical staining showed 
no correlation with lymph node involvement or histological grade (24). 
8. Metastasis suppressor genes 
8.1 E-cadherin 
E-cadherin (a member of the cadherin superfamily of Ca2+-dependent adhesion cell surface 
molecules, expressed predominantly in epithelial tissues) has been demonstrated to 
correlates negatively with the potential of tumor invasion. Reduction and/or loss of E-
cadherin expression in carcinomas will result in increased tumor metastasis because of the 
reduction in tumor cell adhesiveness and increased cell motility (49) 
Tissue Inhibitors of Metalloproteinases 
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The role of metalloproteinases (TIMPs) is inhibiting the activity of matrix proteinases 
(MMPs). As a result, they suppress tumor metastasis. An interesting paradox is that 
increased TIMPs are associated with progression to metastatic disease in some studies. One 
proposed explanation is that the balance between MMPs and TIMPs is important than the 
expression of each protein (50).  
8.2 Maspin 
Maspin (belonging to the serpin family of serine protease inhibitors) is a tumor suppressor 
gene which has been established to be involved at least in breast and prostate cancer. Loss of 
maspin expression has been established during immunohistochemical studies (51). 
8.3 Kai1 
Kangai 1 (from Chinese kang ai meaning anticancer) or Kai1 is a member of the 
Transmembrane-4 superfamily of adhesion molecules and is involved in lymphocyte 
differentiation and function. It was originally described as a metastasis suppressor in 
prostate cancer but its role has been established as a general suppressor of the metastatic 
phenotype in many cancer types including breast cancer, although KAI1 does not affect 
primary tumor growth (52). 
8.4 BRMS1 
Breast cancer metastasis-suppressor 1 (BRMS1) decreases metastatic potential of tumor cells, 
although tumorigenicity do not affected. The mechanism underlying BRMS1 tumor 
suppression is not yet known, but some data suggest that this role may be mediated by 
enhanced immune recognition, altered transport, and/or secretion of metastasis-associated 
proteins (53). 
8.5 MKK4 
This gene encodes a dual specificity protein kinase that belongs to the Ser/Thr protein 
kinase family. This kinase is a direct activator of MAP kinases in response to various 
environmental stresses or mitogenic stimuli. It has been shown to activate MAPK8/JNK1, 
MAPK9/JNK2, and MAPK14/p38, but not MAPK1/ERK2 or MAPK3/ERK3. This kinase is 
phosphorylated, and thus activated by MAP3K1/MEKK (54). 
8.6 Role of micro-RNAs 
A newly opened window in cancer studies is the discovery of microRNAs (mi RNAs). It has 
been noticed that alteration of non-coding genes, including miRNAs is related to cancer 
pathogenesis. Mi RNAs modulate the expression of many genes through cleaving mRNA 
molecules or inhibiting their translation. As a result, they are involved in a variety of 
physiological and pathological processes, including development, differentiation, cellular 
proliferation, programmed cell death, cancer initiation and metastasis. It is important to 
note that a single miRNA can influence the expression of hundreds of proteins. Early studies 
showed that compared to normal breast human tissues, miRNAs are extensively 
deregulated in breast tumors. MiRNAs exert their influences at several steps of tumor 
development and metastasis. Cancer cell adherence, migration, invasion, motility, and 
angiogenesis are all affected by these modulators. “Metastamir” is the name which has been 
applied for the class of miRNAs which are involved in metastasis associated processes. 
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Profiling of metastamirs in human breast cancer has been resulted in to find the new 
molecular mechanisms in metastatic process. Significant increase in expression of some of 
miRNAs has been identified in breast tumors and some others have shown some correlation 
with biopathological features such as Her2, ER and PR status, tumor stage, and response to 
treatments. The most important miRNAs involved in different steps of developing breast 
tumor are miR-335, miR-17/20, and miR-146 (involved inmicroenvironment modification), 
let-7, miR-200 and miR-30 (BCSC phenotype formation); miR-21,miR- 12 6, miR-373, and 
miR-520 (local invasion), miR-7, miR-661 and miR-17/20 (survival in vasculature ) and miR-
200 and let-7 (proliferation at distant sites). 
Chemoresistance is also affected by miRNAs. Some miRNAs which play some roles in this 
step are miR-125b, miR-21, and miR -128. The mechanisms underlying miRNAs 
dysregulation in breast cancer development, whether dysregulated miRNA is a cause or 
consequence of pathological and many other questions remain to be explored (55). Some of 
the most important miRNAs have been mentioned in table 1. 
 
miRNA involved Protein inhibited Function influenced 
miR-7 EGFR Anoikis resistance 
miR-30 Ubc 9 Anoikis resistance 
miR-520 CD 44 Local invasion 
miR-373 CD 44 Local invasion 
miR-21 Bcl-2 Colonization 
miR-145 IRS-1 Colonization 
miR-17/20 Cyclin D1 Colonization 
MiR-205 VEGF Angiogenesis 
MiR-9 E-cadherin Angiogenesis 
Table 1. miRNAs and their function in cancer 
9. Biomarkers 
Identifying biomarkers in early stages of breast cancer as helpful instruments for increasing 
breast cancer survival has opened an important window in researches. 
Immunohistochemical testing of tumor samples for estrogen receptor(ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER 2) is a common method 
which is widely used (56,57). Biomarkers in biological fluids are more useful because they 
don’t need biopsy and invasive methods. Four metabolic biomarkers including 
Homovanillate, 4-hydroxyphenylacetate, 5-hydroxyindoleacetate and urea have been shown 
to be different in urine samples of cancer subjects, compared to control group (58). The 
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intraductal sampling including samples of nipple aspiration, ductal lavage, and duct 
endoscopy, is newly used for direct access to the microenvironment surrounding the breast 
cells that are undergoing malignant transformation (59).  
Serum antigens and autoantibody profiling is another approach for early detection and 
diagnosis of breast cancer. Elevation in level of two antigens, CA 15-3 and CA 27.29, has 
been reported. Another way is detection of serum autoantibodies against tumor suppressor 
genes. Studying the changes appeared in level of several autoantibodies instead of only one 
antibody appears preferable to achieve more accuracy. 
BRCA1/2 mutation or functional losses are the other markers will likely serve as a useful 
predictive biomarker for diagnosis as well as of response to treatment with PARP inhibitors.  
REGǄ (also known as PA28Ǆ, PSME3 or Ki antigen) is a member of the REG or 11S family of 
proteasome activators which bind to 20S proteasome and facilitate the related degradation 
of its intracellular protein substrates. REGǄ is one of the potential markers in breast cancer 
whose expression is associated with breast cancer development and the presence of ER, 
CerBb-2 and lymph node metastasis. It has been reported that REGǄ could facilitate the 
growth of breast cancer cells. Abnormal high expression of REGǄ has been observed in 
breast cancer and its metastatic lymph nodes (60). 
BCL2 has been introduced as an independent biomarker for prognosis of all types of early-
stage breast cancers. Immunohistochemical studies have been introduced BCL2 expression 
as a new diagnostic instrument in breast cancer studies although further work should be 
done to ascertain the exact way to apply BCL2 testing for risk estimation and to find a 
standard protocol for BCL2 immunohistochemistry (61). 
Ki-67, MI, PCNA, and LI have been reported as markers for poor prognosis, although the 
most important one has not been established yet (62). Serum associated tumor markers have 
been newly introduced for breast cancer diagnosis. Carbohydrate antigen (CA) 15-3 and 
carcinoembryonic antigen (CEA) are the most well-known markers. The noticeable point is 
that the elevation of CA 15-3 between 4 and 6 weeks after initiation of a new therapy, i.e. 
spurious early rise (surge), indicates poor prognosis. However, American Society of Clinical 
Oncology (ASCO) guidelines don’t recommend CA 15-3 alone as a marker for either 
diagnosis or detection of early recurrence of breast cancer. CEA expression level has been 
not also confirmed as a marker for diagnosis or routine surveillance after primary therapy. 
The ASCO recommend CEA level measurement as supplementary information (63). 
Overexpression of cathepsin B (CTSB) - which is involved in proteolytic pathways that lead 
to the degradation of ECM proteins - and caveolin-1 (cav-1) - which is correlated with 
increased expression of RhoC and resultant increase in cell motility and invasion - have 
been established in Inflammatory breast cancer (IBC) compared to non-IBC tissues. 
Furthermore, CTSB expression level has shown a significant positive correlation with the 
number of positive metastatic lymph nodes in IBC (and not in non-IBC patients). IBC is the 
most invasive and fatal form of primary breast cancer, the 3-year survival rate for this kind 
of breast cancer is 40% which compared to 85% for non- IBC, is very poor. Distinct clinical 
features of this form include a rapid onset, erythema, edema of the breast and a “peaud’ 
orange” appearance of the skin. High metastatic behavior, rapid invasion into blood and 
lymphatic vessels and formation of tumor emboli within these vessels are also major 
characteristics of IBC which make this form the most dangerous kind of breast cancer (64).  
MTDH/AEG-1overexpression or genomic amplification can also be used as biomarker to 
identify subgroups of patients with requirement for more aggressive treatment, although 
more studies should be done (40). 
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PKC (a family of serine/threonine kinases involved in several cellular signaling pathways 
including proliferation, differentiation, apoptosis, and migration) is a marker associated 
with poor prognosis of breast cancer. Although most breast cancers are PKCa -negative, the 
small PKCa-positive ratio shows more aggressiveness (65). 
S100A4 protein expression appears to be elevated in early and advanced stages of breast 
cancer compared to normal breast, although its role in different stages of breast cancer 
seems to be complex. Compared to early stage, S100A4 protein has been observed to down 
regulate in more advanced stages of breast cancer (66). 
Aldehyde dehydrogenase 1 (ALDH1) tumor cell expression is an independent predictor of 
BRCA1 mutation status. Since BRCA1 related breast cancers consist of increased cancer stem 
cell components, these hereditary tumors shows significantly elevated expression of 
ALDH1. ALDH1 positive population of breast cancer cells show high tumorigenic capacity 
through serial passages in vitro, compared with A LDH1 negative population. ALDH1 
tumor cell expression has been introduced as an independent predictor of BRCA1 mutation 
status. Furthermore, ALDH1 might be useful as a BRCA1 biomarker and therapeutic target 
(67). High saturated to monounsaturated fatty acid ratio measured in blood is another 
indicator associated with breast cancer risk. Low activity or reduced expression of stearoyl-
CoA desaturase-1 will result in a decreased breast cancer risk. The suppression of 
stearoylCoA desaturase expression leads to reduction of cell proliferation and invasion in 
vitro, and impairs tumor formation and growth which could not be overcome by use of 
exogenous monounsaturated fatty acids. Since high saturated to monounsaturated fatty acid 
ratiois related to the activity of this enzyme, it can be used as a new marker to assume breast 
cancer risk, although more studies should be done.  
Since SCD-1 expression is regulated by dietary and lifestyle factors, new nutritional 
strategies for cancer prevention could be focused on SCD1 function (68).  
Newly introduced Metastamirs assume to be useful biomarkers for prediction of 
progression and prognosis of breast cancer and in identification of the novel targets for 
therapeutic intervention in future breast cancer diagnosis and treatment (55). 
Taken together, our knowledge about molecular pathways involved in breast cancer and 
prognostic and diagnostic markers are much more than before, although many works 
remain to be done. 
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